Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Vétoquinol UK Ltd
Address: Vétoquinol House
Great Slade
Buckingham Industrial Park
Buckingham
MK18 1PA
Telephone: 01280 814500
Fax: 01280 825460
Email: office@vetoquinol.co.uk
Website: www.vetoquinol.co.uk
Presentation
Yellow-orange transparent gel for oral administration. Each ml contains acepromazine (as acepromazine maleate) 35.0 mg and methyl-4-hydroxybenzoate 0.65 mg and propyl-4-hydroxybenzoate 0.35 mg as preservatives.
Uses
For sedation of horses
Dosage and administration
Moderate sedation: 0.15 mg acepromazine/kg bodyweight.
The dose may be varied to administer between ½ and 1 ½ times the above recommendation according to the level of sedation required, i.e. for mild sedation, administer half the recommended dose and for deeper sedation, administer 1 ½ times the recommended dose.
Because of the difficulties in ensuring the accurate delivery of small doses, the product should only be used in horses of less than 200kg bodyweight in accordance with a benefit / risk assessment by the responsible veterinarian.
The syringe is brought into the animal’s mouth and the suitable dose is pumped into the cheek pouch. The palatable Gel can also be mixed with food.
Contra-indications, warnings, etc
Not for use in animals in shock or post traumatically, or with existing severe emotional excitation or epilepsy.
Special warnings for each target species
Sedation lasts for approximately six hours, although the actual time and depth of sedation are very dependent on the status of the individual animal.
Increasing the dosage results in prolonged action and side effects but no greater sedation.
Special precautions for use in animals
Do not use in cases of post traumatic hypovolemia.
Operator warning
In the case of accidental ingestion contact a physician showing the pack insert or product label to the physician. Wash hands and exposed skin thoroughly after use. Persons with sensitive skin or in continuous contact are advised to wear impermeable gloves. Avoid contact with eyes. If accidental eye contact occurs, flush gently with running water for 15 minutes and seek medical advice if any irritation persists.
Adverse reactions (frequency and seriousness)
Since acepromazine decreases sympathetic nervous system tone, a transient drop in blood pressure may occur after its administration. Acepromazine inhibits temperature regulation.
The following reversible changes are possible in the haemogram: Transient decrease in the erythrocyte count and haemoglobin concentration as well as in thrombocyte and leukocyte counts.
Because it increases prolactin secretion, the administration of acepromazine may lead to disturbances in fertility.
Penile prolapse may occur due to the relaxation of the retractor penis muscles. Retraction of the penis should be visible within two to three hours. If this does not take place, it is advised to contact a veterinary surgeon. Lack of retraction is of particular concern in breeding stallions. Acepromazine has caused paraphimosis sometimes in a sequel to priapism.
Use during pregnancy or lactation
Acepromazine should not be used in pregnant or lactating mares.
In stallions the lowest dose range is indicated to minimise prolapse of the penis.
Interaction with other medicinal products and other forms of interaction
Acepromazine potentiates the action of centrally depressant drugs. The simultaneous use of organic phosphate esters increases the toxicity of acepromazine. Since acepromazine decreases sympathetic nervous system tone, it should not be given at the same time as blood pressure reducing drugs.
Overdose (symptoms, emergency procedures, antidotes) if necessary
Overdosage results in an earlier onset of the sedative symptoms and in a prolonged effect.
Toxic effects are: ataxia, hypotensia, hypothermia, extrapyramidal effects.
Noradrenaline can be used to counteract the cardiovascular effects. Methylamphetamine has been recommended for the treatment of aberrant reactions in horses.
Withdrawal period
Not for use in animals intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.
Incompatibilities
Simultaneous administration or administration to patients who were treated recently with organophosphates should be avoided, since these molecules enhance the toxic effects of acepromazine.
Simultaneous treatment with blood pressure lowering products should be avoided.
Pharmaceutical Precautions
Keep out of reach of children.
Do not store above 25°C.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
10 ml white, low density polyethylene pre-filled oral dial-a-dose syringe and syringe plunger with white low density polyethylene cap (push fit)
Further information
ATC Vet Code: QN05AA04 Acepromazine is a phenothiazine derivate. This group of molecules belongs to the neuroleptica: they depress the central nervous system and exert associated effects on the autonomic system. These effects are due to their interference with different neurotransmitter receptors (dopaminergic, adrenergic) and to their interference with hypothalamic performance.
The desired effects observed after treatment with acepromazine include a general tranquillizing effect, anti-emetic effect and a slight antihistaminic effect. There is no analgesic action. The neuroleptical effects are variable between individual animals.
Acepromazine is partly absorbed from the gastrointestinal tract. It binds extremely well to plasma proteins and is extensively distributed over the body tissues. Plasma levels are usually low. Acepromazine is highly metabolized and excreted in urine. The sedative activity starts within 15-30 minutes and lasts up to 6-7 hours.
Marketing authorisation number
Vm 08007/4089.
| 
